Minerva Neurosciences Names New CBO as President Exits

Event summary

  • Geoff Race, Minerva’s President, departs after 16 years; will consult during transition.
  • Jim O’Connor, ex-Axena Health executive, named CBO effective April 21, 2026.
  • O’Connor brings 20+ years of legal/business leadership in life sciences and tech.
  • Minerva focuses on advancing roluperidone for negative schizophrenia symptoms.
  • Phase 3 trial for roluperidone is the next critical milestone.

The big picture

Minerva’s leadership shift comes at a critical juncture as it prepares for a Phase 3 trial for roluperidone, a potential first-of-its-kind therapy for schizophrenia. The appointment of Jim O’Connor, with his cross-industry experience, signals a focus on operational rigor and strategic transactions. The biopharmaceutical sector is increasingly valuing leadership with both scientific and business acumen to navigate complex clinical and regulatory pathways.

What we're watching

Trial Execution
Whether Minerva can successfully navigate the next Phase 3 trial for roluperidone, a pivotal step for FDA approval.
Leadership Impact
How Jim O’Connor’s operational and legal expertise will shape Minerva’s strategic direction and financial discipline.
Market Positioning
The pace at which Minerva can differentiate roluperidone in a competitive CNS therapeutics landscape.